Brainstorm Cell Therapeutics (BCLI) Short Interest Ratio & Short Volume $0.72 +0.03 (+4.06%) As of 03:58 PM Eastern Add Compare Share Share Short Interest Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock Brainstorm Cell Therapeutics Short Interest DataBrainstorm Cell Therapeutics (BCLI) has a short interest of 604,500 shares, representing 7.91% of the float (the number of shares available for trading by the public). This marks a 30.48% increase in short interest from the previous month. The short interest ratio (days to cover) is 0.4, indicating that it would take 0.4 days of the average trading volume of 689,372 shares to cover all short positions.Current Short Interest604,500 sharesPrevious Short Interest463,300 sharesChange Vs. Previous Month+30.48%Dollar Volume Sold Short$677.04 thousandShort Interest Ratio0.4 Days to CoverLast Record DateJune 30, 2025Outstanding Shares9,839,000 sharesFloat Size7,640,000 sharesShort Percent of Float7.91%Today's Trading Volume70,219 sharesAverage Trading Volume689,372 sharesToday's Volume Vs. Average10% Short Selling Brainstorm Cell Therapeutics? Sign up to receive the latest short interest report for Brainstorm Cell Therapeutics and its competitors with MarketBeat's FREE newsletter. Email Address Skip Charts & View Short Interest HistoryShort Interest ChartDays to Cover ChartShort Percent of Float ChartBCLI Short Interest Over TimeBCLI Days to Cover Over TimeBCLI Percentage of Float Shorted Over Time Brainstorm Cell Therapeutics Short Interest History Export to ExcelReport DateTotal Shares Sold ShortDollar Volume Sold ShortChange from Previous ReportPercentage of Float ShortedDays to CoverPrice on Report Date 6/30/2025604,500 shares $677.04 thousand +30.5%7.9%0.4 $1.12 6/15/2025463,300 shares $509.63 thousand -13.7%7.5%0.4 $1.10 5/31/2025536,900 shares $617.33 thousand +156.3%8.7%0.4 $1.15 5/15/2025209,500 shares $243.02 thousand -28.1%3.4%0.2 $1.16 4/30/2025291,400 shares $378.82 thousand -16.0%5.2%1.8 $1.30 4/15/2025346,700 shares $269.73 thousand +152.7%6.8%2.5 $0.78 3/31/2025137,200 shares $172.87 thousand +11.7%2.7%3.3 $1.26 3/15/2025122,800 shares $195.25 thousand +14.6%2.8%2 $1.59 2/28/2025107,200 shares $171.52 thousand -3.3%2.4%1.6 $1.60 2/15/2025110,900 shares $206.27 thousand +21.3%2.5%1.4 $1.86 Get the Latest News and Ratings for BCLI and Related StocksEnter your email address below to receive the latest news and analysts' ratings for Brainstorm Cell Therapeutics and its competitors with MarketBeat's FREE daily newsletter. 1/31/202591,400 shares $166.35 thousand -47.2%2.1%0.9 $1.82 1/15/2025173,000 shares $354.65 thousand +85.4%3.9%1.7 $2.05 12/31/202493,300 shares $211.79 thousand -38.8%2.1%0.8 $2.27 12/15/2024152,400 shares $220.98 thousand +2.8%3.1%1.4 $1.45 11/30/2024148,200 shares $257.87 thousand -14.8%3.0%1.6 $1.74 11/15/2024173,900 shares $210.42 thousand +58.4%3.6%2.3 $1.21 10/31/2024109,800 shares $205.33 thousand -33.8%2.3%1.7 $1.87 10/15/2024165,900 shares $351.71 thousand +33.2%3.4%3.6 $2.12 9/30/2024124,600 shares $28.70 thousand -91.1%2.6%3.6 $0.23 9/15/20241,400,000 shares $394.80 thousand +8.5%N/A3.2 $0.28 8/31/20241,290,000 shares $398.61 thousand -20.4%N/A2.4 $0.31 8/15/20241,620,000 shares $507.38 thousand +51.4%N/A2.9 $0.31 7/31/20241,070,000 shares $366.15 thousand -0.9%N/A1.9 $0.34 7/15/20241,080,000 shares $450.36 thousand -26.5%N/A1.8 $0.42 6/30/20241,470,000 shares $497.60 thousand +65.1%N/A1.9 $0.34 6/15/2024890,600 shares $418.58 thousand -20.5%N/A1 $0.47 5/31/20241,120,000 shares $544.99 thousand -20.6%N/A1.2 $0.49 5/15/20241,410,000 shares $682.44 thousand -32.9%N/A1.4 $0.48 4/30/20242,100,000 shares $792.75 thousand +5.5%N/A2.1 $0.38 4/15/20241,990,000 shares $1.09 million +48.5%N/A2 $0.55 3/31/20241,340,000 shares $756.70 thousand +57.6%N/A1.3 $0.56 3/15/2024850,300 shares $283.06 thousand -20.5%N/A0.6 $0.33 2/29/20241,070,000 shares $392.69 thousand -13.0%N/A0.7 $0.37 2/15/20241,230,000 shares $477.24 thousand -39.4%N/A0.5 $0.39 1/31/20242,030,000 shares $717.20 thousand -15.1%N/A0.8 $0.35 1/15/20242,390,000 shares $781.29 thousand -43.2%N/A0.9 $0.33 12/31/20234,210,000 shares $1.15 million +25.3%N/A1.5 $0.27 12/15/20233,360,000 shares $789.60 thousand -4.0%N/A0.9 $0.24 11/30/20233,500,000 shares $976.50 thousand -7.2%N/A1.1 $0.28 11/15/20233,770,000 shares $689.91 thousand +5.6%N/A1.6 $0.18The End of Elon Musk…? (Ad)The End of Elon Musk? Don't make him laugh. Jeff Brown has been hearing this same tired story for years, and he's been proven right time and time again. And now, while the media focuses on Tesla's "demise," he's uncovered an AI breakthrough that's about to make Elon's doubters eat their words yet again. According to his research, if you listen to the media and miss out on Elon's newest breakthrough, it's going to cost you the fortune of a lifetime.Click here to see why the "End of Elon" crowd is about to be wrong again. 10/31/20233,570,000 shares $546.21 thousand -20.5%9.8%1.9 $0.15 10/15/20234,490,000 shares $763.30 thousand +1.1%12.4%2.6 $0.17 9/30/20234,440,000 shares $888.44 thousand +26.1%12.2%3 $0.20 9/15/20233,520,000 shares $3.39 million +9.3%9.7%9.3 $0.96 8/31/20233,220,000 shares $5.51 million +21.1%9.2%13.4 $1.71 8/15/20232,660,000 shares $4.15 million No Change7.6%11.3 $1.56 7/31/20232,660,000 shares $4.89 million -5.3%8.6%12 $1.84 7/15/20232,810,000 shares $5.54 million +0.4%9.1%12.1 $1.97 6/30/20232,800,000 shares $5.77 million +2.9%9.1%11.7 $2.06 6/15/20232,720,000 shares $7.37 million -5.6%8.8%6.7 $2.71 5/31/20232,880,000 shares $8.21 million +0.4%9.6%7.2 $2.85 5/15/20232,870,000 shares $7.92 million -9.2%9.5%8 $2.76 4/30/20233,160,000 shares $9.13 million +7.9%11.3%7.8 $2.89 4/15/20232,930,000 shares $8.23 million -5.5%10.4%7.3 $2.81 3/31/20233,100,000 shares $10.23 million +29.7%11.0%7.7 $3.30 3/15/20232,390,000 shares $3.87 million +0.8%8.5%10.2 $1.62 2/28/20232,370,000 shares $5.36 million +3.0%8.4%10.6 $2.26 2/15/20232,300,000 shares $5.24 million +18.6%8.1%9.6 $2.28 1/31/20231,940,000 shares $3.53 million -1.5%6.9%7 $1.82 1/15/20231,970,000 shares $2.88 million -3.9%7.0%8.3 $1.46 12/30/20222,050,000 shares $3.36 million -9.3%7.3%8.9 $1.64 12/15/20222,260,000 shares $4.09 million No Change8.0%9.6 $1.81 11/30/20222,260,000 shares $3.73 million -12.4%8.0%8.8 $1.65 11/15/20222,580,000 shares $4.46 million -4.1%9.1%9.8 $1.73 10/31/20222,690,000 shares $9.58 million +10.3%9.5%11.1 $3.56 10/15/20222,440,000 shares $8.49 million +23.2%8.7%10.2 $3.48 9/30/20221,980,000 shares $8.75 million +52.3%7.0%8.9 $4.42 9/15/20221,300,000 shares $5.59 million +68.2%4.6%7.2 $4.30 8/31/2022772,900 shares $2.80 million +36.6%2.7%5.3 $3.62 8/15/2022565,900 shares $1.95 million -5.4%2.0%4.8 $3.45 7/31/2022598,200 shares $1.53 million +3.1%2.1%9.8 $2.56 7/15/2022580,300 shares $1.53 million -9.5%3.2%9.5 $2.64 6/30/2022641,300 shares $1.77 million -0.1%3.6%10.7 $2.76 6/15/2022642,100 shares $1.83 million -4.9%3.6%10.2 $2.85 5/31/2022675,200 shares $1.99 million +5.6%2.4%10.6 $2.94 5/15/2022639,600 shares $1.74 million +6.6%2.3%9.7 $2.72 4/30/2022600,200 shares $1.80 million -2.1%2.1%9.1 $3.00 4/15/2022612,800 shares $1.93 million -8.5%2.2%8.6 $3.15 3/31/2022669,400 shares $2.25 million -8.4%2.4%8.4 $3.36 3/15/2022731,100 shares $2.30 million -0.6%2.6%5.1 $3.15 2/28/2022735,200 shares $2.24 million -7.0%2.6%2.4 $3.05 2/15/2022790,200 shares $2.47 million -22.5%2.8%2.1 $3.12 1/31/20221,020,000 shares $3.18 million -9.7%3.3%2.5 $3.12 1/15/20221,130,000 shares $4.01 million -17.5%3.6%2.7 $3.55 12/31/20211,370,000 shares $5.48 million +11.4%4.4%3.3 $4.00 12/15/20211,230,000 shares $4.05 million +32.1%3.9%3.3 $3.29 11/30/2021931,500 shares $3.54 million +27.1%3.1%4.2 $3.80 11/15/2021732,900 shares $2.23 million -1.4%2.4%4.8 $3.04 10/29/2021743,600 shares $2.16 million -11.5%2.5%6.3 $2.90 10/15/2021839,800 shares $2.59 million -14.4%2.8%5.9 $3.08The End of Elon Musk…? (Ad)The End of Elon Musk? Don't make him laugh. Jeff Brown has been hearing this same tired story for years, and he's been proven right time and time again. And now, while the media focuses on Tesla's "demise," he's uncovered an AI breakthrough that's about to make Elon's doubters eat their words yet again. According to his research, if you listen to the media and miss out on Elon's newest breakthrough, it's going to cost you the fortune of a lifetime.Click here to see why the "End of Elon" crowd is about to be wrong again. 9/30/2021981,000 shares $3.24 million +6.8%3.3%6.6 $3.30 9/15/2021918,700 shares $3.24 million -11.7%3.1%4.1 $3.53 8/31/20211,040,000 shares $3.61 million No Change3.5%4.3 $3.47 8/13/20211,040,000 shares $3.83 million +16.3%3.5%3.5 $3.68 7/30/2021894,200 shares $3.60 million -32.3%3.0%2.7 $4.03 7/15/20211,320,000 shares $4.51 million -5.7%4.4%3.6 $3.42 6/30/20211,400,000 shares $5.32 million -60.9%4.7%3.4 $3.80 6/15/20213,580,000 shares $14.21 million +0.3%11.9%6.3 $3.97 5/28/20213,570,000 shares $12.78 million -18.5%11.9%5.8 $3.58 5/14/20214,380,000 shares $14.10 million +14.7%N/A6 $3.22 4/30/20213,820,000 shares $13.41 million +4.1%N/A4.4 $3.51 4/15/20213,670,000 shares $12.92 million -16.4%N/A3.2 $3.52 3/31/20214,390,000 shares $16.29 million +4.0%N/A3.8 $3.71 3/15/20214,220,000 shares $18.06 million +7.4%N/A3.5 $4.28 2/26/20213,930,000 shares $15.60 million -6.9%N/A3.4 $3.97 2/12/20214,220,000 shares $30.00 million -9.4%N/A3.2 $7.11 1/29/20214,660,000 shares $29.38 million -2.9%N/A3.1 $6.31 1/15/20214,800,000 shares $24.05 million -11.1%N/A3.6 $5.01 12/31/20205,400,000 shares $25.00 million -15.2%N/A4.1 $4.63 12/15/20206,370,000 shares $33.06 million -5.9%N/A4.9 $5.19 11/30/20206,770,000 shares $35.54 million +5.5%N/A5.7 $5.25 11/15/20206,420,000 shares $74.79 million +7.5%N/A6.1 $11.65 10/30/20205,970,000 shares $64.18 million +17.5%N/A10.2 $10.75 10/15/20205,080,000 shares $84.79 million +12.1%N/A8.4 $16.69 9/30/20204,530,000 shares $76.65 million +18.3%N/A8.7 $16.92 9/15/20203,830,000 shares $54.19 million -1.5%N/A6 $14.15 8/31/20203,890,000 shares $49.05 million +8.1%N/A5.5 $12.61 8/14/20203,600,000 shares $47.77 million +2.9%N/A4.8 $13.27 7/31/20203,500,000 shares $47.43 million -20.8%N/A4.8 $13.55 BCLI Short Interest - Frequently Asked Questions What is Brainstorm Cell Therapeutics' current short interest? Short interest is the volume of Brainstorm Cell Therapeutics shares that have been sold short but have not yet been covered or closed out. As of June 30th, investors have sold 604,500 shares of BCLI short. 7.91% of Brainstorm Cell Therapeutics' shares are currently sold short. Learn More on Brainstorm Cell Therapeutics' current short interest. What is a good short interest percentage for Brainstorm Cell Therapeutics? Companies that have a short interest as a percentage of float below 10% indicates positive investor sentiment and few short sellers. Stocks with a short interest percentage above 10% is considered high, suggesting some investors are pessimistic about the stock. Companies with a short interest percentage of 20% or more indicates widespread negative sentiment. 7.91% of Brainstorm Cell Therapeutics' floating shares are currently sold short. Is Brainstorm Cell Therapeutics' short interest increasing or decreasing? Brainstorm Cell Therapeutics saw a increase in short interest in June. As of June 30th, there was short interest totaling 604,500 shares, an increase of 30.5% from the previous total of 463,300 shares. Changes in short volume can be used to identify positive and negative investor sentiment. Investors that short sell a stock are betting that its price will decline in the future. An increase in short sale volume suggests bearish (negative) sentiment among investors. A decrease on short sale volume suggests bullish (positive) sentiment. What is Brainstorm Cell Therapeutics' float size? Brainstorm Cell Therapeutics currently has issued a total of 9,839,000 shares. Some of Brainstorm Cell Therapeutics' outstanding shares are available for trading, while others are subject to various restrictions. The public float, also referred to as floating shares or "the float", are shares that publicly owned, unrestricted and available to trade on the open market. Brainstorm Cell Therapeutics currently has a public float of 7,640,000 shares. How does Brainstorm Cell Therapeutics' short interest compare to its competitors? 7.91% of Brainstorm Cell Therapeutics' shares are currently sold short. Here is how the short interest of companies in the industry of "pharmaceutical products" compare to Brainstorm Cell Therapeutics: Dyadic International Inc. (0.54%), SCYNEXIS, Inc. (1.63%), Enlivex Therapeutics Ltd. (0.94%), NeuroSense Therapeutics Ltd. (2.27%), Generation Bio Co. (1.67%), NanoViricides, Inc. (1.62%), ALX Oncology Holdings Inc. (14.41%), Q32 Bio Inc. (5.99%), FibroBiologics Inc. (2.74%), Rani Therapeutics Holdings, Inc. (14.19%), Which stocks are the most shorted right now? As of the most recent reporting period, the following stocks had the largest short interest positions: SPDR S&P 500 ETF Trust ($72.10 billion), Invesco QQQ ($26.89 billion), iShares Russell 2000 ETF ($19.61 billion), MicroStrategy Incorporated ($9.52 billion), iShares 20+ Year Treasury Bond ETF ($8.70 billion), WD-40 Company ($7.66 billion), Technology Select Sector SPDR Fund ($6.10 billion), Invesco S&P 500 Equal Weight ETF ($5.80 billion), Invesco S&P 500 Top 50 ETF ($5.53 billion), and Vanguard Large-Cap ETF ($5.35 billion). View all of the most shorted stocks. What does it mean to sell short Brainstorm Cell Therapeutics stock? Short selling BCLI is an investing strategy that aims to generate trading profit from Brainstorm Cell Therapeutics as its price is falling. BCLI shares are trading up $0.03 today. To short a stock, an investor borrows shares, sells them and buys the shares back on the public market later to return it to the lender. Short sellers are betting that a stock will decline in price. If the stock does drop after selling, the short seller buys it back at a lower price and returns it to the lender. The difference between the sell price and the buy price is the trader's profit. How does a short squeeze work against Brainstorm Cell Therapeutics? A short squeeze for Brainstorm Cell Therapeutics occurs when it has a large amount of short interest and its stock increases in price. This forces short sellers to cover their short interest positions by buying actual shares of BCLI, which in turn drives the price of the stock up even further. How often is Brainstorm Cell Therapeutics' short interest reported? Short interest is typically published by a stock exchange once per month. However, NASDAQ publishes a report for U.S. stocks, including BCLI, twice per month. The most recent reporting period available is June, 30 2025. More Short Interest Resources from MarketBeat Related Companies Dyadic International Short Interest Data SCYNEXIS Short Interest Data Enlivex Therapeutics Short Interest Data NeuroSense Therapeutics Short Interest Data Generation Bio Short Interest Data NanoViricides Short Interest Data ALX Oncology Short Interest Data Q32 Bio Short Interest Data FibroBiologics Short Interest Data Rani Therapeutics Short Interest Data Short Interest Tools Stocks to Short Largest Short Interest Positions Short Interest Increases Short Interest Decreases Short Interest Reporting Dates This page (NASDAQ:BCLI) was last updated on 7/25/2025 by MarketBeat.com Staff From Our PartnersYour Bank Account Is No Longer SafeWhat If Washington Declared That: YOUR Money ISN'T Actually Yours? Sounds insane, but that's exactly what ...Priority Gold | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredGoogle did what!?!?A new technology has sparked a modern-day gold rush in Silicon Valley. OpenAI’s Sam Altman invested $375M. Bil...Stansberry Research | SponsoredPresidential Bombshell: $150T Resource to Be Released as soon as this Summer?Something extraordinary is happening in Washington. For the first time in over a century, a sitting Preside...Paradigm Press | SponsoredTrump’s betrayal exposed Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | SponsoredTreasury Secretary Bessent Is Betting Big on GoldWhen the U.S. Treasury Secretary’s largest personal investment is gold — that’s a signal. Now a veteran gol...Golden Portfolio | SponsoredYour blueprint for crypto wealthMark August 12th on your calendar. 27 of crypto's most successful minds are about to reveal everything…Crypto 101 Media | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Brainstorm Cell Therapeutics Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Brainstorm Cell Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
